ampicillin sodium salt

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ampicillin sodium salt
• 英文别名: ampicillin sodium；ampicillin；sodium ampicillin；ampicillin sodiumm salt；C16H18N3NaO4S；sodium;(2R)-2-amino-N-[(2S,5R,6R)-2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-6-yl]-2-phenylethanimidate
• 化学式: C₁₆H₁₈N₃O₄S*Na
• 分子量: 371.392
• InChiKey: KLOHDWPABZXLGI-YWUHCJSESA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -4.01
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  141
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ampicillin sodium salt 在 水 、 sodium hydroxide 作用下， 反应 2.0h， 生成
  参考文献：
  名称：

  Immune Recognition of Closed and Open Lactam Rings and Their Influence on Immunoassays of Ampicillin Antibiotics

  摘要：

  Open-ring derivatives of beta-lactams do not inhibit bacterial growth but retain several biological activities. In this regard, methods of antibiotic control should be characterized by specificity to such derivatives. The objective of this study was to evaluate commercially available immunoreagents for the detection of beta-lactams from the point of view of their selectivity with respect to the open-ring derivatives of lactams. The enzyme-linked immunosorbent assays (ELISA) was used for this purpose. Ampicillin was hydrolyzed by acid and alkaline treatments, and opening of the lectern ring was confirmed spectrophotometrically. It was shown that either selective detection of only native ampicillin or integrated detection of both its states could be realized depending on the immunoreagents. The detection limit for native ampicillin for both assays was 10 ng/mL, where as cross-reactivity to the derivatives with an open ring was <0.01% for the first case and 61.5-64.2% for the second case. The established variability is critical in interpreting the data of immunodetection and should be controlled for grounded evaluation of pharmaceuticals and foods.

  DOI：

  10.13005/ojc/360103
• 作为产物：
  描述：

  氨苄西林 在 三乙胺 、 sodium acetate 、 碳酸氢钠 作用下， 以 丙酮 为溶剂， 生成 ampicillin sodium salt
  参考文献：
  名称：

  一种氨苄西林钠舒巴坦钠的药物组合物的制 备方法

  摘要：

  本发明公开了一种氨苄西林钠舒巴坦钠的药物组合物，由舒巴坦钠和比旋度为+264°～+269°的氨苄西林钠组成，其中氨苄西林钠和舒巴坦钠的质量比为2：1。本发明采用特定比旋度的氨苄西林钠和舒巴坦钠制得，能够提高药物的稳定性，提高用药的安全性。

  公开号：

  CN105520942B
• 作为试剂：
  描述：

  苯甲酸乙酯 在 ammonium hydroxide 、 葡萄糖 、 ampicillin sodium salt 作用下， 以 水 、 paraffin oil 为溶剂， 生成 Ethyl 5,6-dihydroxycyclohexa-1,3-diene-1-carboxylate
  参考文献：
  名称：

  Production of cis-1,2-dihydrocatechols of high synthetic value by whole-cell fermentation using Escherichia coli JM109 (pDTG601): A detailed study

  摘要：

  Chiral cis-1,2-dihydrocatechols have been extensively used as starting materials for the synthesis of complex organic molecules. The preparation of these high added value compounds is carried out mainly by enzymatic dihydroxylation of arenes since no other efficient chemical method is known. In this paper we describe a detailed study of the biotechnological production at a preparative scale of cis-3-bromo-1,2-dihydrocatechol (BDC) from bromobenzene using Escherichia coli JM109 (pDTG601), a recombinant strain that harbors the toluene dioxygenase genes from Pseudomonas putida F1. High cell-density cultures of the microorganism (65 g/L cdw) were achieved in a 5 L bioreactor using fed-batch cultures in aerobic conditions. The influence of the biomass concentration in the volumetric and specific productivity of the system, as well as the kinetics of the biotransformation, was thoroughly studied. The use of liquid paraffin as a second phase to relieve bromobenzene's toxicity resulted in an increased specific productivity for the bi-phasic protocol, which resulted in higher final BDC concentrations. An improvement of 3.2-fold was obtained for BDC production compared to previous reports using this organism. Furthermore, storage strategies of the biocatalytic system as a reagent for organic synthesis are presented. (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molcatb.2013.06.003

文献信息

• [EN] GOLD COMPOUNDS AND THEIR USE IN THERAPY<br/>[FR] COMPOSÉS D'OR ET LEUR UTILISATION DANS LE CADRE D'UNE THÉRAPIE
  申请人：AUSPHERIX LTD

  公开号：WO2018220171A1

  公开（公告）日：2018-12-06

  Compound of formula (I) and pharmaceutically acceptable salts and solvates thereof are described, wherein: Px selected from (P1), (P2) or (P3); The compounds are useful in the prevention or treatment of a bacterial infection.

  描述了化合物的公式（I）及其药用可接受的盐和溶剂化合物，其中：Px选自（P1）、（P2）或（P3）；这些化合物在预防或治疗细菌感染方面是有用的。
• [EN] ANTIFUNGAL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ANTI-FONGIQUES ET UTILISATIONS ASSOCIÉES
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2017143230A1

  公开（公告）日：2017-08-24

  Provided herein are compounds (e.g., compounds of Formulae (I), (II), and (III)) which are anti-fungal agents and can be used in the treatment of diseases, including infectious diseases. The invention provides methods of treating diseases in a subject (e.g., infectious diseases such as fungal infections), and methods of killing or inhibiting the growth of fungi in or on a subject or biological sample. The compounds may be used in subjects, in clinical settings, or in agricultural settings.

  本发明提供了化合物（例如，公式(I)、(II)和(III)的化合物），这些化合物是抗真菌剂，可用于治疗包括传染性疾病在内的疾病。本发明还提供了在主体（例如，真菌感染等传染性疾病）中治疗疾病的方法，以及杀死或抑制主体或生物样本内或上的真菌生长的方法。这些化合物可用于主体、临床环境或农业环境。
• Dihydropyrancarboxamides and uses thereof
  申请人：——

  公开号：US20040059138A1

  公开（公告）日：2004-03-25

  The present invention provides novel dihydropyrancarboxamide compounds of formula (I): 1 and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R 1 -R 6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.

  本发明提供了式（I）的新颖二氢吡喃羧酰胺化合物： 1 以及这些化合物的集合，并提供了合成这些化合物的方法；其中R 1 -R 6 如本文所定义。此外，本发明提供了用于治疗增殖性疾病和癌症等疾病的药物组合物和方法。
• [EN] TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF<br/>[FR] INHIBITEURS DE TOPOISOMÉRASE DE TYPE II ET PROCÉDÉS DE PRODUCTION ET D'UTILISATION DE CES DERNIERS
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2018195098A1

  公开（公告）日：2018-10-25

  Disclosed are Type II Topoisomerase Inhibitors, analogs thereof, pharmaceutical compositions thereof, and methods of making and using these compounds and compositions. Methods of using the disclosed compounds to treat infections, such as MRSA, MDR P. aeruginosa, and other pathogens are also described.

  披露了II型拓扑异构酶抑制剂及其类似物、药物组合物以及制备和使用这些化合物和组合物的方法。还描述了利用所披露的化合物治疗感染，如MRSA、MDR P. aeruginosa和其他病原体的方法。
• [EN] DIBENZOFURAN DERIVATIVES WITH ANTIBACTERIAL AND WOUND-HEALING ACTIVITY<br/>[FR] DÉRIVÉS DE DIBENZOFURANNE À ACTIVITÉ ANTIBACTÉRIENNE ET DE CICATRISATION DE PLAIES
  申请人：UNIV DEGLI STUDI MILANO

  公开号：WO2013189950A1

  公开（公告）日：2013-12-27

  Disclosed are dibenzofuran derivatives of usnic acid, compositions thereof and use thereof in dermatological or cosmetic formularions with antimicrobial, regenerative and anti-aging purposes.

  揭示了乌司酸的二苯并呋喃衍生物，以及它们的组合物，并将其用于具有抗菌、再生和抗衰老作用的皮肤科或化妆品配方中。